The Japanese Pharmacopoeia (JP) is primarily required for marketing authorization in: Response:

The correct answer is C. Japan. Japan maintains the Japanese Pharmacopoeia (JP) as its official national drug standards compendium, making it a mandatory reference for pharmaceutical companies seeking marketing authorization specifically within Japan - not globally. The United States (A) uses the United…

Question

The Japanese Pharmacopoeia (JP) is primarily required for marketing authorization in:

Response:

Options

AThe United States
BEurope
CJapan
DAll countries worldwide

How the community answered

(28 responses)

A
4% (1)
B
18% (5)
C
71% (20)
D
7% (2)

Explanation

Japan maintains the Japanese Pharmacopoeia (JP) as its official national drug standards compendium, making it a mandatory reference for pharmaceutical companies seeking marketing authorization specifically within Japan - not globally. The United States (A) uses the United States Pharmacopeia (USP), and Europe (B) relies on the European Pharmacopoeia (Ph. Eur.), each region maintaining its own sovereign standards body. Option D is incorrect because no single pharmacopoeia holds universal worldwide authority; the ICH (International Council for Harmonisation) works toward alignment, but national/regional pharmacopoeias remain jurisdiction-specific requirements.

Memory tip: Match the pharmacopoeia to its flag - JP = Japan, USP = USA, Ph. Eur. = Europe. Each "home country" requires its own pharmacopoeia for drug approval.

Community Discussion

No community discussion yet for this question.

Full CPGP Practice